REVIVA PHARMACEUTICALS
1.1400
27-November-24 16:45:00
15 minutes delayed
Stocks
+0.0200
+1.79%
Today's range
1.1100 - 1.2200
ISIN
N/A
Source
NASDAQ
-
09 May 2024 08:00:00 By Nasdaq GlobeNewswire
-
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
15 Apr 2024 08:30:00 By Nasdaq GlobeNewswire
-
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
15 Apr 2024 08:05:00 By Nasdaq GlobeNewswire
-
28 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
-
26 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
-
Reviva to Present at the UBS Virtual CNS Day
11 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
-
Reviva to Present at the 36th Annual ROTH Conference
07 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
-
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
20 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
-
06 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
-
25 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
-
Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones
04 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
-
Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
11 Dec 2023 08:00:00 By Nasdaq GlobeNewswire
-
30 Nov 2023 16:05:00 By Nasdaq GlobeNewswire
-
20 Nov 2023 16:05:00 By Nasdaq GlobeNewswire
-
Reviva Announces $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
16 Nov 2023 08:00:00 By Nasdaq GlobeNewswire
-
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
14 Nov 2023 16:01:00 By Nasdaq GlobeNewswire
-
30 Oct 2023 07:30:00 By Nasdaq GlobeNewswire
-
25 Sep 2023 06:00:00 By Nasdaq GlobeNewswire
-
Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
07 Sep 2023 06:00:00 By Nasdaq GlobeNewswire